Because mutation in FLT3 gene is one of the most common driver mutations in AML and confers poor prognosis, we utilized primary AML cells with or without FLT3-ITD mutation (see Table S1 for further details on clinical characteristics). This evidence concerns the gene FLT3 and acute myeloid leukemia.